Preview

Научно-практическая ревматология

Расширенный поиск

Первый опыт использования флударабина в лечении пациента с рефрактерным течением гранулематоза Вегенера

https://doi.org/10.14412/1995-4484-2012-1277

Полный текст:

Список литературы

1. <div><p>Wegener F. On generalised septic vessel diseases. Thorax 1987;42:918-9.</p><p>Godman G.C., Churg J. Wegener's granulomatosis: pathology and review of the literature. AMA Arch Path 1954;58:533-53.</p><p>Leavitt R.Y., Fauci A.S., Bloch D.A. et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthr Rheum 1990;33:1101-7.</p><p>Jennette J.C., Falk R.J., Andrassy K. et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthr Rheum 1994;37:187-92.</p><p>Hoffman G.S., Kerr G.S., Leavitt R.Y. et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.</p><p>Reinhold-Keller E., Beuge N., Latza U. et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthr Rheum 2000;43:1021-32.</p><p>Yi E.S., Colby T.V. Wegener Granulomatosis. Semin Diagn Pathology 2001;18:34-46.</p><p>Bosch X., Guilabert A., Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-18.</p><p>Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford) 2002;41:481-3.</p><p>Hewins P., Tervaert J.W., Savage C.O. et al. Is Wegener's granulomatosis an autoimmune disease? Curr Opin Rheumatol 2000;12:3-10.</p><p>Hellmich B., Flossmann O., Gross W.L. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.</p><p>Hunder G.G., Arend W.P., Bloch D.A. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: Introduction. Arthr Rheum 1990;33:1065-7.</p><p>Bloch D.A., Michel B.A., Hunder G.G. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods. Arthr Rheum 1990;33:1068-73.</p><p>Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001;13:48-55.</p><p>Schmitt W.H., Hagen E.C., Neumann I. et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004;65:1440-8.</p><p>Langford C.A., Hoffman G.S. Wegener's granulomatosis. Thorax 2000;54:629-37.</p><p>Novack S.N., Pearson C.M. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971;284:938-42.</p><p>Fauci A.S., Wolff S.M. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973;52:535-61.</p><p>Hoffman G.S., Kerr G.S., Leavitt R.Y. et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.</p><p>Reinhold-Keller E., Beuge N., Latza U. et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthr Rheum 2000;43:1021-32.</p><p>Stone J.H., Merkel P.A., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.</p><p>Jones R.B., Tervaert J.W., Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.</p><p>de Groot K., Harper L., Jayne D.R. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.</p><p>Jayne D.R., Gaskin G., Rasmussen N. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.</p><p>de Groot K., Rasmussen N., Bacon P.A. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthr Rheum 2005;52:2461-9.</p><p>Rutgers A., Kallenberg C.G.M. Refractory vasculitis. Autoimmun Rev 2011;10:702-6.</p><p>Ramos-Casals M., Garcia-Hernandez F.J., de Ramon E. et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010;28:468-76.</p><p>Jones R.B., Ferraro A.J., Chaudhry A.N. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthr Rheum 2009;60:2156-68.</p><p>Roccatello D., Baldovino S., Alpa M. et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008;26:S67-S71.</p><p>Seo P., Specks U., Keogh K.A. Efficacy of rituximab in limited Wegeners granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008;35:2017-23.</p><p>Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthr Rheum 2006;54:2970-82.</p><p>Stasi R., Stipa E., Del Poeta G. et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006;45:1432-6.</p><p>Keogh K.A., Ytterberg S.R., Fervenza F.C. et al. Rituximab for refractory Wegeners granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.</p><p>Walsh M., Chaudhry A., Jayne D. Long-term follow-up of relapsing/refractory antineutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1 H). Ann Rheum Dis 2008;67:1322-7.</p><p>Benenson E., Fries J.W., Heilig B. et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegeners granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 2005;24:251-7.</p><p>Bartolucci P., Ramanoelina J., Cohen P. et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-32.</p><p>Booth A., Harper L., Hammad T. et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibodyassociated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.</p><p>Birck R., Warnatz K., Lorenz H.M. et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.</p><p>Flossmann O., Baslund B., Bruchfeld A. et al. Deoxyspergualin in relapsing and refractory Wegeners granulomatosis. Ann Rheum Dis 2009;68:1125-30.</p><p>Stassen P.M., Tervaert J.W., Stegeman C.A. Induction of remission in active antineutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802.</p><p>Statkute L., Oyama Y., Barr W.G. et al. Autologous nonmyeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann Rheum Dis 2008;67:991-7.</p><p>Kotter I., Daikeler T., Amberger C. et al. Autologous stem cell transplantation of treatment-resistant systemic vasculitis-a single center experience and review of the literature. Clin Nephrol 2005;64:485-9.</p><p>Schlieben D.J., Korbet S.M., Kimura R.E. et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005;45:758-61.</p><p>Xiao H., Heeringa P., Hu P. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.</p><p>Bolton W.K., Innes D., Sturgill B.C., Kaiser D.L. T cells and macrophages in rapidly progressive glomerulonephritis: Clinicopathological correlates. Kidney Int 1987;32:869-76.</p><p>Csernok E., Trabandt A., Muller A. et al. Cytokine profiles in Wegener's granulomatosis: predominace of type 1 (Th1) in the granulomatous inflammation. Arthr Rheum 1999;42:742-50.</p><p>Balding C.E.J., Howie A.J., Drake-Lee A.B., Savage C.O.S. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 2001;125:332-9.</p><p>Komocsi A., Lamprecht P., Csernok E. et al. Peripheral blood and granuloma CD4+ CD28- T cells are a major source of interferon-а and tumor necrosis factor-а in Wegener's granulomatosis. Am J Pathol 2002;160:1717-24.</p><p>Cunningham M.A., Huang X.R., Dowling J.P. et al. Effectors of cellmediated immunity are prominent in “pauci-immune” glomerulonephritis. J Am Soc Nephrol 1999;10:499-506.</p><p>Lamprecht P., Moosig F., Csernok E. et al. CD28 negative T cells are enriched in the granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 2001;56:751-7.</p><p>Van der Woude F.J., van Es L.A., Daha M.R. The role of c-ANCA antigen in the pathogenesis of Wegener's granulomatosis. A hypothesis based on both humeral and cellular mechanisms. Neth J Med 1990;36:169-71.</p><p>Brouwer E., Stegeman C., Muitema M. et al. T-cell reactivity to proteinase 3 and myeloperoxidase in patients withWegener's granulomatosis. Clin Exp Immunol 1994;98:448-53.</p><p>King W.J., Brooks C.J., Holder R. et al. T lymphocyte responses to anti-neutrophil cytoplasmic antibody (ANCA) antigens are present in patients with ANCA associated systemic vasculitis and persist during disease remission. Clin Exp Immunol 1998;112:539-46.</p><p>Popa E.R., Franssen C.F., Limburg P.C. et al. In vitro cytokine production and proliferation of T cells from patients with antiproteinase 3-and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthr Rheum 2002;46:1894-904.</p><p>Brouwer E., Tervaert J.W., Horst G. et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 1991;83:379-86.</p><p>Schmitt W.H., Heesen C., Csernok E. et al. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthr Rheum 1992;35:1088-96.</p><p>Wang G., Csernok E., Gross W.L. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997;102:517-23.</p><p>Ludviksson B.J., Sneller M.C., Chua K.S. et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602-9.</p><p>Plunkett W., Gandhi V., Cheson B. et al. Cellular pharmacology, mechanisms of action and strategies for combination therapy. In: Cheson B., Keating M., Plunkett W. (eds). Nucleoside analogs in cancer therapy. New York: Marcel Dekker, 1997;1 —35.</p><p>Frank D.A., Mahajan S., Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999;5:444-7.</p><p>Meng H., Yang C., Ni W. et al. Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo. Eur J Haematol 2007;79:486-93.</p></div><br />


Для цитирования:


Городецкий В.Р., Васильев В.И., Седышев С.Х., Ogorodnikova M.D., Божьева Л.А., Насонов Е.Л. Первый опыт использования флударабина в лечении пациента с рефрактерным течением гранулематоза Вегенера. Научно-практическая ревматология. 2012;50(2):76-80. https://doi.org/10.14412/1995-4484-2012-1277

For citation:


Gorodetsky V.R., Vasilyev V.I., Sedyshev S.Kh., Ogorodnikova M.D., Bozhyeva L.A., Nasonov E.L. The first experience with fludarabine used to treat a patient with refractory Wegener's granulomatosis. Rheumatology Science and Practice. 2012;50(2):76-80. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1277

Просмотров: 586


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)